Australian public assessment for Nivolumab

The use of checkpoint inhibitors has been associated with a unique spectrum of side effects termed ‘immune related adverse events’ (irAEs). Management of moderate or severe irAEs requires interruption of the checkpoint inhibitor and the use of immunosuppression (usually corticosteroid). ................
................